An Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence
Abstract
Psychopharmacological treatments for methamphetamine (MA) dependence have questionable efficacy. Open-label risperidone was evaluated in veterans seeking MA dependence treatment. Participants (N = 11) received four weeks of risperidone. They provided weekly self-reports of substance use, urine drug screens, and adverse effects. Neuropsychological assessments and psychiatric symptomatology (Brief Symptom Inventory; BSI) were measured at baseline and follow-up. The eight completers had an average risperidone dose of 3.6 mg/day and decreased days of MA use during the trial from a mean of 13.0 (SD = 6.5) in the 30 days prior to starting risperidone to a mean of 0.125 (SD = 0.4; t = 5.7, p = .001), When measured over time, fine motor function (Grooved Peg Board Dominant Hand) was the only neuropsychological domain to improve significantly. No other domain changed significantly from baseline to follow-up among study completers. BSI data were converted to demographically corrected T-scores utilizing appropriate normative data (mean = 50, SD = 10). BSI somatization T-scores declined from a mean of 59.0 (SD = 8.4) to 51.8 (SD = 8.3; t = 2.7, p <.05), and positive symptom distress declined from a mean of 52.8 (SD =8.0) to 41.7 (SD = 8.6; t= 3.0, p <.05). Risperidone was well tolerated and associated with decreased MA use.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Risperidone has shown promise for the treatment of methamphetamine abuse, and aripiprazole is a promising treatment for amphetamine abuse.
“Finally, risperidone, a D2-receptor antagonist, has shown promise for the treatment of methamphetamine abuse [182], and aripiprizole, a partial D2 agonist is a promising treatment for amphetamine abuse [183].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [182]
Cites
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650 · see citing works
THE AMERICAN JOURNAL OF PSYCHIATRY
Dunton, W. R. (1944) · American Journal of Psychiatry · doi:10.1176/ajp.100.6.45 · Cited by 3,849 · see citing works
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476 · see citing works
Wechsler Adult Intelligence Scale--Third Edition
Wechsler, D. (2019) · PsycTESTS Dataset · doi:10.1037/t49755-000 · Cited by 2,327 · see citing works
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597 · see citing works
Clinical neuropsychology: Current status and applications
(1975) · Behavior Therapy · doi:10.1016/s0005-7894(75)80088-8 · Cited by 1,556 · see citing works
Limbic Activation During Cue-Induced Cocaine Craving
Childress, A. R., Mozley, P. D., McElgin, W., Fitzgerald, J., Reivich, M., & O’Brien, C. P. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.11 · Cited by 1,513 · see citing works
Borkowski, J. G., Benton, A. L., & Spreen, O. (1967) · Neuropsychologia · doi:10.1016/0028-3932(67)90015-2 · Cited by 1,324 · see citing works
Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine Abusers
Volkow, N. D., Chang, L. L., Wang, G., Fowler, J. S., Leonido–Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., HITZEMANN, R. J., Ding, Y. ‐., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.377 · Cited by 984 · see citing works
(1969) · Occupational Therapy the Official Journal of the Association of Occupational Therapists · doi:10.1177/030802266903200417 · Cited by 983 · see citing works
Corticotropin-releasing factor, norepinephrine, and stress
Koob, G. F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00164-x · Cited by 629 · see citing works
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602 · see citing works
Bilder, R. M., GOLDMAN, R. S., Volavka, J., Czobor, P., Hoptman, M. J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538 · see citing works
Golden, C. J., Freshwater, S. M., & Golden, Z. L. (2002) · PsycTESTS Dataset · doi:10.1037/t06065-000 · Cited by 449 · see citing works
Compulsive Drug‐Seeking Behavior and Relapse: Neuroadaptation, Stress, and Conditioning Factors
WEISS, F., CICCOCIOPPO, R., PARSONS, L. H., KATNER, S., LIU, X., ZORRILLA, E. P., VALDEZ, G. R., BEN‐SHAHAR, O., ANGELETTI, S., & RICHTER, R. R. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03556.x · Cited by 430 · see citing works
Receptor pharmacology of neuroleptics: relation to clinical effects.
Richelson, E. (1999) · PubMed · Cited by 307 · see citing works
Alpha-2 Adrenergic Receptor Agonists Block Stress-Induced Reinstatement of Cocaine Seeking
Erb, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00158-x · Cited by 270 · see citing works
Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence
Grabowski, J. G., Shearer, J., Merrill, J., & Negus, S. S. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.06.018 · Cited by 257 · see citing works
Stuber, G. D., Roitman, M. F., Phillips, P. E. M., Carelli, R. M., & Wightman, R. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300619 · Cited by 217 · see citing works
Stahl, S. M., Zhang, L., Damatarca, C., & Grady, M. M. (2003) · PubMed · Cited by 202 · see citing works
Dopamine transport function is elevated in cocaine users
Mash, D. C., Pablo, J. P., Ouyang, Q., Hearn, W. L., & Izenwasser, S. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00820.x · Cited by 167 · see citing works
Stahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0102 · Cited by 154 · see citing works
Malison, R. T., Best, S. E., van Dyck, C. H., McCance, E. F., Wallace, E. A., Laruelle, M. A., Baldwin, R. M., Seibyl, J. P., Price, L. H., Kosten, T. R., et al. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.832 · Cited by 154 · see citing works
Cecchi, M., Khoshbouei, H., & Morilak, D. A. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00292-7 · Cited by 147 · see citing works
Stahl, S. M., & Shayegan, D. K. (2003) · PubMed · Cited by 146 · see citing works
A Comparison of Patterns of Methamphetamine and Cocaine Use
Simon, S. L., Richardson, K., Dacey, J., Glynn, S. M., Domier, C. P., Rawson, R. A., & Ling, W. W. (2001) · Journal of Addictive Diseases · doi:10.1300/j069v21n01_04 · Cited by 144 · see citing works
The effect of relapse on cognition in abstinent methamphetamine abusers
Simon, S. L., Dacey, J., Glynn, S., Rawson, R., & Ling, W. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.03.011 · Cited by 142 · see citing works
Prazosin, an α-1 Adrenergic Antagonist, Reduces Cocaine-Induced Reinstatement of Drug-Seeking
Zhang, X. Y., & Kosten, T. A. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.003 · Cited by 118 · see citing works
The Matrix Model of Outpatient Stimulant Abuse Treatment:
SHOPTAW, S. J., Rawson, R. A., McCann, M. J., & Obert, J. L. (1995) · Journal of Addictive Diseases · doi:10.1300/j069v13n04_02 · Cited by 117 · see citing works
Striatal Dopaminergic Abnormalities in Human Cocaine Users
Little, K. Y., Zhang, L., Desmond, T., Frey, K. A., Dalack, G. W., & Cassin, B. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.238 · Cited by 116 · see citing works
Risperidone for the Treatment of Cocaine Dependence: Randomized, Double-Blind Trial
Grabowski, J. G., Rhoades, H. M., Silverman, P. B., Schmitz, J. M., Stotts, A. L., Creson, D., & Bailey, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00003 · Cited by 116 · see citing works
Integrating treatments for methamphetamine abuse: A psychosocial perspective
Huber, A., Ling, W. W., SHOPTAW, S. J., Gulati, V., Brethen, P., & Rawson, R. A. (1997) · Journal of Addictive Diseases · doi:10.1080/10550889709511142 · Cited by 105 · see citing works
Word-list generation deficits in dementia
Barr, A., & Brandt, J. (1996) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688639608408304 · Cited by 105 · see citing works
Risperidone Attenuates the Discriminative-Stimulus Effects of d-Amphetamine in Humans
Rush, C. R., Stoops, W. W., Hays, L. R., Glaser, P. E. A., & Hays, L. R. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048439 · Cited by 86 · see citing works
On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization
Vanderschuren, L. J. M. J., Beemster, P. W. T., & Schoffelmeer, A. N. M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1509-8 · Cited by 83 · see citing works
A pilot trial of olanzapine for the treatment of cocaine dependence
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Sparkman, T., & O’Brien, C. P. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00009-7 · Cited by 83 · see citing works
Weickert, T. W., Goldberg, T. E., Marenco, S., Bigelow, L. B., Egan, M. F., & Weinberger, D. R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300216 · Cited by 76 · see citing works
A controlled trial of imipramine for the treatment of methamphetamine dependence
Galloway, G. P., Newmeyer, J. A., Knapp, T., Stalcup, S. A., & Smith, D. E. (1996) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(96)00154-7 · Cited by 71 · see citing works
Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine
Newton, T. F., Ling, W. W., Kalechstein, A. D., Uslaner, J. M., & Tervo, K. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00255-4 · Cited by 58 · see citing works
Malison, R. T., Best, S. E., McCance, E. F., Laruelle, M. A., Baldwin, R. M., Seibyl, J. P., Price, L. H., Kosten, T. R., Innis, R. B., Hoffer, P. B., et al. (1995) · Psychopharmacology · doi:10.1007/bf02246266 · Cited by 58 · see citing works
Imipramine for the Treatment of Cocaine and Methamphetamine Dependence
Galloway, G. P., Newmeyer, J. A., Knapp, T., Stalcup, S. A., & Smith, D. E. (1995) · Journal of Addictive Diseases · doi:10.1300/j069v13n04_08 · Cited by 55 · see citing works
On-Line Manuscript Submission and Peer Review
(2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0102 · Cited by 44 · see citing works
Bohus, B., Koolhaas, J. M., Korte, S. M., Roozendaal, B., & Wiersma, A. (1996) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1996.tb02593.x · Cited by 31 · see citing works
Arnt, J. (1992) · Behavioural Pharmacology · doi:10.1097/00008877-199203010-00004 · Cited by 27 · see citing works
Wong, J. L. (1994) · Journal of Clinical Psychology · doi:10.1002/1097-4679(199407)50:4 · Cited by 27 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works
“Finally, risperidone, a D2-receptor antagonist, has shown promise for the treatment of methamphetamine abuse [182], and aripiprizole, a partial D2 agonist is a promising treatment for amphetamine abuse [183].”
BackgroundPharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242 · see citing works
Pharmacotherapy of amphetamine-type stimulant dependence: An update
Brensilver, M., Heinzerling, K., & Shoptaw, S. (2013) · Drug and Alcohol Review · doi:10.1111/dar.12048 · Cited by 122 · see citing works
“mixed dopamine and serotonin antagonist risperidone in small samples of methamphetamine-dependent adults to show acceptability [30] and decreases in weekly methamphetamine use that correlated with plasma risperidone levels [31].”
BackgroundTreatments for Methamphetamine Abuse
Brackins, T., Brahm, N. C., & Kissack, J. C. (2011) · Journal of Pharmacy Practice · doi:10.1177/0897190011426557 · Cited by 93 · see citing works
“The half-life of aripiprazole is approximately 60 hours.(23) Sessions with the aripiprazole active treatment arm were likely scheduled too close together.”
BackgroundPharmacotherapy for amphetamine dependence: A systematic review
Lee, N., Jenner, L., Harney, A., & Cameron, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.06.038 · Cited by 85 · see citing works
Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder
Ling, W. W., Chang, L., Hillhouse, M. P., Ang, A., Striebel, J. M., Jenkins, J., Hernandez, J. C., Olaer, M., Mooney, L. J., Reed, S. W., et al. (2014) · Addiction · doi:10.1111/add.12608 · Cited by 81 · see citing works
“Antipsychotics (aripiprazole, risperidone), anti-epileptics (topiramate, vigabatrin, gabapentin) and other agents (dextroamphetamine, odansetron, varenicline, baclofen, modafinil, N-acetyl cysteine+naltrexone, and the proprietary approach Prometa) either failed to demonstrate efficacy or have yet to be studied in larg…”
BackgroundNew horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 73 · see citing works
Wang, J., Kelly, B., Booth, B., Falck, R., Leukefeld, C., & Carlson, R. (2009) · Addictive Behaviours · doi:10.1016/j.addbeh.2009.08.003 · Cited by 81 · see citing works
“The BSI has also been used in different types of research including clinical studies of pharmacotherapy for methamphetamine dependence (Meredith et al, 2007), therapy for couples in substance abuse treatment (Li et al., 2007), and studies of anti-retroviral adherance among drug users (Knowlton et…”
MethodValeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41 · see citing works
“Meredith et al. (2007) administered eight methamphetamine users with a 4-week open label risperidone treatment at the average dosage of 3.6mg/day, demonstrating a reduction of somatization and psychotic symptom distress over time.”
BackgroundFactorial structure of the Brief Symptom Inventory (BSI)-18 among Chinese drug users
Wang, J., Kelly, B. C., Liu, T., Zhang, G., & Hao, W. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.06.017 · Cited by 33 · see citing works
“, 2007), clinical studies of pharmacotherapy for dependent individuals (Meredith et al., 2007), and studies of anti-retroviral adherence among drug users (Knowlton et al.”
BackgroundAdvances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34 · see citing works
Wang, G., Zhang, Y., Zhang, S., Chen, H., Xu, Z., Schottenfeld, R. S., Hao, W., & Chawarski, M. C. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.11.009 · Cited by 32 · see citing works
Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Yates, J. R. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s431273 · Cited by 30 · see citing works
“503 Relatedly, L-type calcium channels are upregulated in regions such as frontal cortex and limbic forebrain following CPP of various drugs, including METH, 504 with upregulation being dependent on activation of dopamine receptors.”
BackgroundInfluentialOpen Trial of Injectable Risperidone for Methamphetamine Dependence
Meredith, C. W., Jaffe, C., Cherrier, M. M., Robinson, J. P., Malte, C. A., Yanasak, E. V., Kennedy, A., Ferguson, L. C., Tapp, A. M., & Saxon, A. J. (2009) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31818e2185 · Cited by 23 · see citing works
Self-citationKapitány‐Fövény, M., Mervó, B., Kertész, M., Corazza, O., Farkas, J., Kökönyei, G., Urbán, R., & Demetrovics, Z. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2490 · Cited by 17 · see citing works
“On the basis of former findings (e.g. Zweben et al., 2004; Booth et al., 2006; Meredith et al., 2007; Payer et al., 2008; Zorick et al., 2010; Solomon et al., 2010; Darke et al., 2011) we expected more severe psychiatric symptoms and more frequent mephedrone use among injectors.”
BackgroundBanks, M. L. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13276 · Cited by 18 · see citing works
Epidemiological trends and the advances of treatments of amphetamine‐type stimulants (ATS) in China
Sun, H., Chen, H., Yang, F., Lü, L., & Kosten, T. R. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12116.x · Cited by 14 · see citing works
Peña, I. D., Shen, G., & Shi, W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.015 · Cited by 13 · see citing works
“Studies in humans suggest that the euphoric effect of psychostimulants is blocked or reduced by D2 receptor antagonists, suggesting its dependence on D2 receptors (e.g., Brauer and de Wit, 1996; Meredith et al., 2007).”
Peters, M. M. M. S., Park, C. H. J., Turner, A., Guérin, A., & Kim, J. H. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100064 · Cited by 9 · see citing works
Akdağ, E., Kayır, H., & Uzbay, T. I. (2010) · Synapse · doi:10.1002/syn.20886 · Cited by 11 · see citing works
“Thus, these data are in line with the hypothesis that risperidone may be useful in treating, if not preventing, the stimulant-type of addiction-related behaviors (Albanese and Suh, 2006; Meredith et al., 2007).”
ResultWang, G., Ma, L., Liu, X., Yang, X., Zhang, S., Yang, Y., Xu, Z., & Hao, W. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00656 · Cited by 9 · see citing works
“In our study, patients took paliperidone ER at a fixed dose of 3 mg/ day [equivalent to risperidone 2 mg/day (29)], which was lower than the flexible dose range of 1 to 4 mg/day of oral risperidone or the fixed dose of 25 mg of injectable risperidone every 2 weeks used in earlier studies (16, 17).”
BackgroundResultThe effect of memantine on behavioural sensitisation to methamphetamine in mice
Landa, L., Šlais, K., & Šulcová, A. (2012) · Veterinární Medicína · doi:10.17221/6366-vetmed · Cited by 7 · see citing works
“A challenge dose of a methamphetamine + sertindole combination given to animals repeatedly pre-treated with methamphetamine inhibited locomotion compared to the 1st methamphetamine dose, which is similar to observations made in human subjects dependent on methamphetamine, who were given another D2 receptor antagonist…”
Stimulants: Caffeine, Cocaine, Amphetamine, and Other Stimulants
DeVido, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-33404-8_12 · Cited by 7 · see citing works
Rush, C. R., Vansickel, A. R., & Stoops, W. W. (2011) · doi:10.1002/9781118023150.ch14 · Cited by 5 · see citing works
Repetitive administration of aripiprazole enhances locomotor response to methamphetamine in mice
Cheng, M.-C., Hsu, S.-H., & Chen, C. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.09.002 · Cited by 4 · see citing works
The effect of sertindole on behavioural sensitisation to methamphetamine in mice
Landa, L., Šlais, K., & Šulcová, A. (2012) · Veterinární Medicína · doi:10.17221/6468-vetmed · Cited by 4 · see citing works
Amphetamine and Methamphetamine
Barceloux, D. G. (2012) · doi:10.1002/9781118105955.ch1 · Cited by 3 · see citing works
Chougule, A., Adarkar, S. A., Kadam, K., & Parkar, S. (2018) · Journal of Medical Society · doi:10.4103/jms.jms_65_17 · Cited by 2 · see citing works
Methamphetamine psychosis, the efficacy of atypical antipsychotics
Ardanı, A. R., & Nasab, A. M. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.17463/rcm.2015.01.003 · Cited by 2 · see citing works
“Results demonstrated a decrease in meth consumption in abusers (39).”
BackgroundDwoskin, L. P., Glaser, P. E. A., & Bardo, M. T. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_52 · Cited by 1 · see citing works
Pharmacological Trials for the Treatment of Substance Use Disorders
Merlo, L. J., Arana, J., & Stone, A. M. (2010) · doi:10.1002/9780470749180.ch11 · Cited by 1 · see citing works
Machielsen, M. W. J. (2014) · UvA-DARE (University of Amsterdam)
Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China
Sun, H., Chen, H., Yang, F., Lü, L., & Kosten, T. R. (2013) · American Journal on Addictions · doi:10.1111/j.1521-0391.2013.12116.x
Treatment of Methamphetamine withdrawal in trauma patients
Phillips, B., Snyder, S., Safa, H., Wu, J., Shahid, M. M., Turco, L. M., Schroeder, A., Weber, W., & Asensio, J. A. (2017) · Integrative Clinical Medicine · doi:10.15761/icm.1000101
Substance Use in HIV Populations
Truong, T. T., & David, E. H. (2023) · doi:10.1093/med/9780197679098.003.0026
Truong, T. T. (2025) · doi:10.1093/med/9780197812631.003.0034
Alhifany, A. A., Shahbar, A. N., Alzahrani, M., Dighriri, I. M., Alatawi, Y. M., Hamdan, S., Eldaous, A. M., Almahroqi, A. A., Alnuhait, M., & Althobaiti, Y. S. (2026) · Journal of Substance Use · doi:10.1080/14659891.2026.2725088
- Authors
- Meredith, C. W., Jaffe, C., Yanasak, E., Cherrier, M., & Saxon, A. J.
- Affiliations
- University of Washington (US)
- VA Puget Sound Health Care System (US)
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2007-06
- Volume
- 39
- Issue
- 2
- Pages
- 167-172
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- OpenAlex
- W2029748394
- Cited by
- 37
- References
- 46
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 4
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychoactive Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- risperidone, methamphetamine dependence, veterans, antipsychotic pharmacotherapy, substance use reduction, neuropsychological performance, fine motor function, psychiatric symptoms, somatization, adverse effects, drug tolerance
- MeSH terms
- Adult, Central Nervous System Stimulants, Female, Humans, Male, Methamphetamine, Middle Aged, Neuropsychological Tests, Pilot Projects, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Antipsychotic Agents, United States, Veterans, Risperidone, Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
